Literature DB >> 12672993

1-methyl-2-undecyl-4(1H)-quinolone as an irreversible and selective inhibitor of type B monoamine oxidase.

Myung Koo Lee1, Bang Yeon Hwang, Seon A Lee, Gab Jin Oh, Woo Hoi Choi, Seong Su Hong, Kyong Soon Lee, Jai Seup Ro.   

Abstract

The inhibitory compound of monoamine oxidase (MAO) activity was isolated from the CH(2)Cl(2) fraction of the fructus of Evodia rutaecarpa and identified as 1-methyl-2-undecyl-4(1H)-quinolone (1). Compound 1 showed a selective inhibition of type B MAO (MAO-B) activity with the IC(50) value of 15.3 microM using a substrate kynuramine, but did not inhibit type A MAO (MAO-A) activity. The kinetic analysis using Lineweaver-Burk plots indicated that compound 1 competitively inhibited MAO-B activity with the K(i) value of 9.91 microM. The inhibition of MAO-B by compound 1 was found to be irreversible by dialysis of the incubation mixture. These results suggest that compound 1 is a potent irreversible inhibitor of MAO-B, and may regulate catecholamine content in the neurons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672993     DOI: 10.1248/cpb.51.409

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  8 in total

1.  Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia.

Authors:  Young Kyoung Jang; Chul Hyoung Lyoo; Seongbeom Park; Seung Jun Oh; Hanna Cho; Minyoung Oh; Young Hoon Ryu; Jae Yong Choi; Gil D Rabinovici; Hee Jin Kim; Seung Hwan Moon; Hyemin Jang; Jin San Lee; William J Jagust; Duk L Na; Jae Seung Kim; Sang Won Seo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

Review 2.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

Review 3.  Selective MAO-B inhibitors: a lesson from natural products.

Authors:  Simone Carradori; Melissa D'Ascenzio; Paola Chimenti; Daniela Secci; Adriana Bolasco
Journal:  Mol Divers       Date:  2013-11-12       Impact factor: 2.943

4.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

Authors:  Kok Pin Ng; Tharick A Pascoal; Sulantha Mathotaarachchi; Joseph Therriault; Min Su Kang; Monica Shin; Marie-Christine Guiot; Qi Guo; Ryuichi Harada; Robert A Comley; Gassan Massarweh; Jean-Paul Soucy; Nobuyuki Okamura; Serge Gauthier; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2017-03-31       Impact factor: 6.982

5.  18F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia.

Authors:  Gijin Nam; Hye Jin Jeong; Jae Myeong Kang; Sang-Yoon Lee; Seongho Seo; Ha-Eun Seo; Kee Hyung Park; Byeong Kil Yeon; Tatsuo Ido; Dong Jin Shin; Young Noh
Journal:  Dement Neurocogn Disord       Date:  2019-02-01

6.  Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling.

Authors:  Thomas Filip; Severin Mairinger; Joerg Neddens; Michael Sauberer; Stefanie Flunkert; Johann Stanek; Thomas Wanek; Nobuyuki Okamura; Oliver Langer; Birgit Hutter-Paier; Claudia Kuntner
Journal:  Alzheimers Res Ther       Date:  2021-10-16       Impact factor: 6.982

7.  18F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment.

Authors:  Min Young Chun; Jongmin Lee; Jee Hyang Jeong; Jee Hoon Roh; Seung Jun Oh; Minyoung Oh; Jungsu S Oh; Jae Seung Kim; Seung Hwan Moon; Sook-Young Woo; Young Ju Kim; Yeong Sim Choe; Hee Jin Kim; Duk L Na; Hyemin Jang; Sang Won Seo
Journal:  Yonsei Med J       Date:  2022-03       Impact factor: 2.759

8.  Development and validation of an UPLC-ESI-MS/MS method for determination of dehydroevodiamine, limonin, evodiamine, and rutaecarpine in Evodiae Fructus.

Authors:  Yang Zhao; Yunling Zhao; Xin Zhou; Xiaojian Gong
Journal:  Pharmacogn Mag       Date:  2014-07       Impact factor: 1.085

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.